# Chugai Pharmaceutical clinical trials: 63 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 63 trials with Chugai Pharmaceutical as lead sponsor, 6 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chugai Pharmaceutical: 63 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chugai-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 1, 2026 | NCT07617337 | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | Chugai Pharmaceutical | Phase 1 | Recruiting | ALK Positive Non-small Cell Lung Cancer | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617337) |
| November 20, 2025 | NCT07239336 | Study of DONQ52 in Active Celiac Disease | Chugai Pharmaceutical | Phase 2 | Recruiting | Celiac Disease | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239336) |
| August 6, 2025 | NCT07107490 | A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER | Chugai Pharmaceutical | Phase 1 | Recruiting | Extensive Stage Small Cell Lung Cancer | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07107490) |
| June 22, 2025 | NCT07030959 | Study of AUBE00 in Patients With Solid Tumors | Chugai Pharmaceutical | Phase 1 | Recruiting | Solid Tumors | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07030959) |
| December 9, 2024 | NCT06723106 | Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) | Chugai Pharmaceutical | Phase 1 | Enrolling by invitation | Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated... | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723106) |
| April 17, 2024 | NCT06371417 | Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | Chugai Pharmaceutical | Phase 1 | Recruiting | Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated... | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06371417) |
| June 18, 2023 | NCT05907980 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | Chugai Pharmaceutical | Phase 1 | Recruiting | Solid Tumor | 209 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05907980) |
| February 21, 2023 | NCT05735366 | A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors | Chugai Pharmaceutical | Phase 1 | Completed | Solid Tumor | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05735366) |
| January 17, 2023 | NCT05686369 | A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar... | Chugai Pharmaceutical | Observational | Completed | Celiac Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05686369) |
| June 27, 2022 | NCT05433207 | Post-Marketing Drug Intensive Monitoring Surveillance of EDIROL in Patients With Postmenopausal Osteoporosis | Chugai Pharmaceutical | Observational | Unknown | Postmenopausal Osteoporosis | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05433207) |
| June 21, 2022 | NCT05425446 | Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients | Chugai Pharmaceutical | Phase 1 | Completed | Celiac Disease | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05425446) |
| August 26, 2021 | NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | Chugai Pharmaceutical | Phase 1 | Unknown | Hepatocellular Carcinoma (HCC) | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05022927) |
| August 19, 2021 | NCT05012618 | A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Chugai Pharmaceutical | Phase 1 | Terminated | Locally Advanced or Metastatic Solid Tumors | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05012618) |
| April 15, 2021 | NCT04846582 | An Observational Study of Patients With Endometriosis to Evaluate the Usefulness of the MEDL Score, a New Method for Evaluating... | Chugai Pharmaceutical | Observational | Completed | Endometriosis | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04846582) |
| March 26, 2021 | NCT04818983 | The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) | Chugai Pharmaceutical | Observational | Completed | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04818983) |
| January 14, 2021 | NCT04708847 | A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer | Chugai Pharmaceutical | Phase 1 | Completed | Healthy Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04708847) |
| December 2, 2020 | NCT04649216 | Excretion Balance, PK and Metabolism of a Single Oral Dose of \[14C\]PCO371 | Chugai Pharmaceutical | Phase 1 | Completed | Healthy Volunteers | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04649216) |
| August 13, 2020 | NCT04511845 | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Chugai Pharmaceutical | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumors | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04511845) |
| August 6, 2020 | NCT04501497 | Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2) | Chugai Pharmaceutical | Observational | Completed | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 1,221 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04501497) |
| December 24, 2019 | NCT04209179 | A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism | Chugai Pharmaceutical | Phase 1 | Terminated | Hypoparathyroidism | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04209179) |
| September 20, 2019 | NCT04097444 | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | Chugai Pharmaceutical | Phase 2 | Unknown | Metastatic Colorectal Cancer | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04097444) |
| November 21, 2018 | NCT03748901 | PD-L1 Expression in Japanese Renal Cell Carcinoma Patients | Chugai Pharmaceutical | Observational | Completed | Renal Cell Carcinoma | 830 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03748901) |
| August 24, 2018 | NCT03645330 | A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL) | Chugai Pharmaceutical | Observational | Completed | Non-small-Cell Lung Cancer | 1,026 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03645330) |
| November 16, 2016 | NCT02965053 | A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis | Chugai Pharmaceutical | Phase 1 | Completed | Hyperphosphatemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02965053) |
| April 22, 2016 | NCT02748837 | A Study of ERY974 in Patient With Advanced Solid Tumors | Chugai Pharmaceutical | Phase 1 | Completed | Solid Tumors | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02748837) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 20 |
| Phase 1/2 | 2 |
| Phase 2 | 6 |
| Phase 3 | 23 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 49 |
| Recruiting | 6 |
| Terminated | 4 |
| Unknown | 3 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 11 |
| Arthritis, Juvenile | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Hepatitis C, Chronic | 3 |
| Celiac Disease | 3 |
| Colorectal Neoplasms | 2 |
| Antiphospholipid Syndrome | 2 |
| Pemphigoid, Bullous | 2 |
| Behcet Syndrome | 2 |
| Dermatomyositis | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Carcinoma, Hepatocellular | 2 |
| Breast Neoplasms | 2 |
| Anemia | 1 |
| Neoplasms | 1 |
| Osteoporosis, Postmenopausal | 1 |
| Hypoparathyroidism | 1 |
| Hyperphosphatemia | 1 |
| Dermatitis, Atopic | 1 |
| Osteoporosis | 1 |
| Liver Cirrhosis | 1 |
| Humoral Hypercalcemia Of Malignancy | 1 |
| Neoplasm Metastasis | 1 |
| Pain | 1 |
| Alzheimer Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
- [Concierge medicine practices in the United States](https://specstream.ai/data/businesses/concierge-medicine-practices/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
